Conclusions: Compound 5 demonstrates strong potential as a dual cholinesterase inhibitor for Alzheimer’s disease, supported by both in vitro and in silico analyses. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.